Dr. Jacob is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
750 E Adams St
Syracuse, NY 13210Phone+1 315-464-6106Fax+1 315-464-6117
Summary
- Dr. Joseph Jacob is an urologist in Syracuse, NY and is affiliated with multiple hospitals in the area, including Upstate University Hospital and Syracuse Veterans Affairs Medical Center. He received his medical degree from The Ohio State University College of Medicine and has been in practice 7 years. He specializes in surgical oncology and is experienced in testicular neoplasms, kidney neoplasms, urinary bladder neoplasms, and urologic neoplasms.
Education & Training
Indiana University School of MedicineFellowship, Minimally Invasive Urologic Surgery, 2015 - 2017
Indiana UniversityMCR, Clinical Research, 2015 - 2017- Indiana University School of MedicineResidency, Urology, 2010 - 2015
- Indiana University School of MedicineInternship, Surgery, 2010 - 2011
Ohio State University College of MedicineClass of 2010
Certifications & Licensure
NY State Medical License 2017 - 2025
PA State Medical License 2018 - 2018
IN State Medical License 2012 - 2017- American Board of Urology Urology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Start of enrollment: 2022 Mar 01
Roles: Contact
Publications & Presentations
PubMed
- Role of Cytoreductive Nephrectomy in Metastatic Clear Cell Renal cell Carcinoma in the Era of immunotherapy: An Analysis of the National Cancer Database.Maroun Bou Zerdan, Stephanie Niforatos, Swathi Arunachalam, Tamara Jamaspishvili, Roger Wong
Clinical Genitourinary Cancer. 2024-12-01 - Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study.Michael F Basin, Carla M Miguel, Joseph M Jacob, Hanan Goldberg, Petros Grivas
Targeted Oncology. 2024-11-01 - 7 citationsOncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua
Nature Medicine. 2024-08-01
Press Mentions
TAR-200 Monotherapy Shows Greater Than 80% Complete Response Rate in Patients with High-Risk Non-Muscle-Invasive Bladder CancerMay 4th, 2024- TAR-200 Monotherapy Shows Greater Than 80 Percent Complete Response Rate in Patients with High-Risk Non-Muscle-Invasive Bladder CancerMay 7th, 2024
Committees
- Member, Cancer Center Clinical Management and Operations Committee 2017 - Present
Professional Memberships
- Member
- Society of Urologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
